- Report
- January 2026
- 181 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- August 2025
- 184 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- June 2025
- 130 Pages
Global
From €4248EUR$4,850USD£3,687GBP
- Report
- May 2025
- 100 Pages
Global
From €4292EUR$4,900USD£3,725GBP
- Report
- March 2025
- 200 Pages
Global
From €2181EUR$2,490USD£1,893GBP
- Report
- January 2026
- 185 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- January 2026
- 187 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- January 2026
- 185 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- January 2026
- 190 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- January 2026
- 195 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- August 2025
- 181 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- August 2025
- 181 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- January 2026
- 185 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- January 2026
- 183 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- January 2026
- 194 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- January 2026
Global
From €4292EUR$4,900USD£3,725GBP
- Report
- February 2026
- 367 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 268 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 279 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 387 Pages
Global
From €5124EUR$5,850USD£4,447GBP

Thrombolytics are a class of cardiovascular drugs used to treat acute ischemic stroke, myocardial infarction, and pulmonary embolism. They work by breaking down the clot that is blocking the blood vessel, allowing blood to flow freely. Thrombolytics are typically administered intravenously, and can be used in combination with other treatments such as anticoagulants and antiplatelet drugs. The most commonly used thrombolytic is tissue plasminogen activator (tPA), which is a recombinant form of the naturally occurring enzyme plasminogen.
The thrombolytics market is highly competitive, with a number of companies offering products for the treatment of cardiovascular diseases. Some of the major players in the market include Boehringer Ingelheim, Pfizer, Sanofi, Bristol-Myers Squibb, and Merck. Show Less Read more